News

Biotech Growth hikes gearing from zero to 10% to benefit from more M&A after hedge funds dump small drug firms

Biotech Growth (BIOG) fund managers Geoff Hsu and Josh Golomb have raised gearing, or borrowing, to 10.3% after a two-month sell-off they believe will lead to even more bids in a sector where mergers and acquisitions had already surged from 2024 lows.

Updates from the £243m investment trust show Hsu and Golomb have actively managed gearing this year, which they normally keep in a 5%-10% range, as they have responded to changing risks and opportunities in a turbulent market. While gearing can enhance long-term shareholder returns by investing more in a rising market, in the short term it can exacerbated declines when stocks are falling.

Half-year results yesterday showed the pair cut BIOG’s gearing to zero in September from 3% at 31 March as fears of rising US interest rates hit the smaller companies weighted portfolio.

Net asset value (NAV) fell 11.3% in September, reducing the six-month underlying portfolio return to 14.8%, underperforming the 21.6% gain in the Nasdaq Biotechnology index. This was discouraging for shareholders who had seen BIOG rebound 73.4% in the year to March after a four-year bear market. However, a narrowing in the share price discount helped by £15.7m of buybacks meant shareholders actually beat the benchmark with a 22.9% total return.

BIOG’s factsheet for October showed a further 7.4% decline in NAV last month as larger biotech stocks benefited from investors switching out of expensive technology and artificial intelligence stocks to defensive sectors such as healthcare.

By contrast, small-cap biotechs continued to face selling pressure, much of it from over-leveraged hedge funds slashing their exposure to smaller drug developers.

“This degrossing meant that many of the companies we consider high quality that hedge funds held ‘long’ suffered the largest share price declines, while many of the lower quality companies that had been popular ‘shorts’ outperformed as funds covered their short positions,” the managers said.

Having already cut their small-cap holdings by 12 percentage points in the half-year period, the duo continued to reposition and tilt the portfolio further towards large caps.

However, they believe that as yields on US government bonds, or Treasuries, stabilise, small and mid-cap biotech companies “will eventually recover from these transiently depressed levels”.

The half-year period saw BIOG benefit from five bids totalling $8bn for KalVista Pharmaceuticals, Esperion Therapeutics, Nuvalent, AtaiBeckley and Forte Biosciences at premiums of 26% to 58%.

The managers are confident of more to come: “We believe the recent correction in biotech valuations could lead to an acceleration in M&A activity as large pharmaceutical companies seek to augment revenue growth ahead of patent cliffs in the early part of the next decade.

“Opportunistic mid-cap companies also continue to assess potential transactions, further supporting the outlook for M&A across the sector. Against this backdrop, we believe that approximately 75% of our holdings as of 30 September are strong potential candidates for M&A.”

According to figures from Life Science Daily, there have been 44 bids worth $162bn for biotech companies over $1bn this year. By contrast, Factset data quoted in BIOG’s annual report showed $105bn of M&A last year up from just $32bn in 2024.

BIOG shares stand on an 8.6% discount to the value of its investments. At 31 October they had outperformed the Nasdaq Biotechnology’s three-year advance of 81.6% with an 89.5% increase in NAV underpinning a 92.2% total return for shareholders. The five-year figures still show the impact of the 2022 crash with 15.3% NAV and 14.6% share price gains compared to the benchmark’s 51.3% return.

Our view

Gavin Lumsden
Written By Gavin Lumsden

Head of News

Leave a Reply

Your email address will not be published. Required fields are marked *